Fifth, while our GDM model was based on a well-validated protocol and hyperglycemia was confirmed at the time of model induction, we did not perform longitudinal profiling of peripheral metabolic parameters such as plasma insulin, glucose tolerance, or asprosin levels. The gene discussed is FBN1; the disease is Hyperglycemia.